Lidocaine HCl 2%w/w

GP- Caine Gel is a sterile local anesthetic product which contains Lidocaine Hydrochloride USP in a water soluble jelly base. It is used for topical/surface anesthesia. The onset of action is 3-5 minutes. It may be rapidly and almost completely absorbed following topical application to mucous membrane and systemic effects may occur.

Lidocaine works by stopping the sodium ions from passing through the voltage-gated channels. So the signals for pain are stopped even before the signals are formed. Lidocaine binds to the sodium channels. The amide on the lidocaine allows it to act like an amino acid, and interact with the active sites in the sodium channel domains. When the active site has something else interacting with it, then it cannot transfer the sodium ions. The exact residues that lidocaine interacts with is not known, although evidence has been seen that it may interact with the residues Phe-1764 and Tyr-1771. Lidocaine interacts in a 1:1 ratio with the sodium channels. Thus, one molecule of lidocaine can block one molecule of the sodium channels.

• Topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx.
• Reducing gagging during the taking of X-ray pictures and dental impressions.
• Surface anaesthesia of the male and female urethra, topical treatment of painful urethritis,
• Anaesthetic lubrication for endotracheal intubation
• Adequate analgesia in endoscopy
• Relieve pain and itching caused by conditions such as sunburn or other minor burns, insect bites or stings, minor cuts or scratches

Before use on the skin, clean and dry the affected area as directed. Apply a thin layer of medication to the affected area of skin, usually 2 to 3 times a day or as directed.

• Known or suspected hypersensitivity to lidocaine.

Absorption from wound surfaces and mucous membranes is relatively high, especially in bronchial tree. Lidocaine gel should be used with cation in patients   with traumatized mucosa and/or sepsis in the region of the proposed application.  Caution is required in patients with hepatic impairment when the dosage or route of administration is liable to result in high blood levels.

Safe use in early pregnancy has not been established. However, there is no clinical evidence to suggest that exposure of the mother to lidocaine is harmful to the fetus. There is no risk of affecting the child at therapeutic dose levels.

These may result from excessive dosage, inadvertent intravascular injection or injection into highly vascular tissues. Initial signs of light-headedness, dizziness, blurred vision, restlessness, tremors and, occasionally, convulsions are rapidly followed by drowsiness, unconsciousness and respiratory failure. Myocardial depression and hypotension may result in hypoxia, acidosis, heart block and cardiac arrest.Hypersensitivity and allergic reactions may also occur.Epidural anaesthesia is occasionally complicated by urinary retention, faecal incontinence, headache, backache or loss of perineal sensation. Transient paraesthesiae and paraplegia are very rare complications.

Co-administration of oxytocic drugs postpartum may cause severe and prolonged hypertension. The use of lidocaine preparations containing epinephrine during or following the administration of halothane or trichloroethylene creates a risk of cardiac dysrhythmias.

Store between 15⁰c – 25⁰c. Keep out of reach of children .Protect from direct sunlight. Do not refrigerate.

Available in 30 gm Alu Tube